The short version of alpha-MSH fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-25. Anything still debated is marked as such rather than presented as settled.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
The metabolism of xenobiotics is often divided into three phases: modification, conjugation, and excretion. These reactions act in concert to detoxify xenobiotics and remove them from cells. For some chemicals, they may instead lead to an increase in toxicity (toxication).
Carefully research the demand for their potential new product before spending an outlay of company funds. Obtain a patent on the new medicine preventing other companies from producing that medicine for a certain allocation of time. The Inverse Benefit Law describes the relationship between a drug's therapeutic benefits and the socioeconomic status (overall health risk/need) of the population undergoing treatment. The law states that the therapeutic benefit conferred by medical interventions upon a population is inversely proportional to its incidence of disease or socioeconomic need. When designing drugs, the placebo effect must be considered to assess the drug's true therapeutic value. Drug development uses techniques from medicinal chemistry to chemically design drugs. This overlaps with the biological approach of finding targets and physiological effects.
where E is the electric field strength, B is the magnetic field induction, q is the charge of the particle, v is its current velocity (expressed as a vector), and × is the cross product. So the force on an ion in a linear homogenous electric field (an electric sector) is:
Sources: en.wikipedia.org
== Sex identification == The 2002 report on the grave had reported that "This is the only known Iron Age grave to contain both a sword and mirror, raising interesting questions as to the gender significance of both these grave goods", but that "preservation of bone and DNA was too poor to determine the person's sex". A 2016 paper said that "Their combined presence within the burial of a single individual represents a touchstone within the ongoing unraveling of a long-held, interconnected set of reified sex and gender assumptions that have permeated discussions of British Iron Age mortuary contexts" and that "Hillside Farm as a starting point highlights the need to keep in mind the potential significance of any aspect of the burial, not to deny that men and women may have existed, or that certain artifacts may have conveyed a gendered meaning, but to refrain from excluding other routes to identity, personhood, or significance before analysis begins." In 2023, American scientists used new techniques of analysis of dental peptides, which indicated that, with 96% probability, the person in the grave was female.
=== tib-tie === tibalosin (INN) tibeglisene (INN) tibenelast (INN) tibenzate (INN) tibezonium iodide (INN) tibolone (INN) tibric acid (INN) tibrofan (INN) ticabesone (INN) ticagrelor (USAN) ticarbodine (INN) ticarcillin (INN) ticarcillin/clavulanic acid TICE BCG (Organon Teknika Corp) ticlatone (INN) Ticlid ticlopidine (INN) ticolubant (INN) tideglusib (INN) tidembersat (INN) tidiacic (INN) tiemonium iodide (INN) tienilic acid (INN) tienocarbine (INN) tienopramine (INN) tienoxolol (INN)
== Cardiology == In cardiology, genetic conditions such as Brugada syndrome can share features with related disorders caused by mutations in the same gene. An overlap syndrome can be seen whereby a mutation in the SCN5A gene encoding the cardiac sodium channel causes a reduction in the peak sodium current leading to the typical ECG features of Brugada syndrome, but which simultaneously increases the sustained late sodium current leading to the ECG features of Long QT syndrome type 3. Brugada syndrome can also overlap with arrhythmogenic cardiomyopathy due to certain mutations in the plakophilin gene.
Sources: en.wikipedia.org
. It is unitless. The mass range is the range of m/z that a given analyzer can analyze. The speed is the number of spectra lines per unit time that can be generated. Typically, higher resolution requires lower speed, and vice versa. Some mass spectrometers, such as the Fourier transform spectrometers, allow a continuous tradeoff between speed and resolution.
== Distribution and habitat == Clown loaches are native to the islands of Sumatra and Borneo in Indonesia. Clear stream environments provide the optimal habitat for clown loaches, but biannual monsoon flooding forces the fish to move into flooded flood plains, or murky or blackwater rivers or lakes, for 7–8 months of the year, and clown loaches are commonly found in the flood plains of hilly areas. Breeding adults migrate to smaller waterways to spawn annually. In its native habitat, the fish is found in water with a temperature range of 25 to 30 °C (77 to 86 °F), a pH between 5.0 and 8.0, and water hardness between 5 and 12 dH.
At the second trial, the defence called eight medical experts, all university professors, who testified that Sunny's two comas had not been caused by insulin, but by a combination of ingested (not injected) drugs, alcohol, and chronic health conditions. The experts were John Caronna (chairman of neurology, Cornell); Leo Dal Cortivo (former president, U.S. Toxicology Association); Ralph DeFronzo (medicine, Yale University); Kurt Dubowski (forensic pathology, University of Oklahoma); Daniel Foster (medicine, University of Texas Southwestern); Daniel Furst (medicine, University of Iowa); Harold Lebovitz (director of clinical research, State University of New York); Vincent Marks (clinical biochemistry, Surrey, vice-president Royal College of Pathologists and president, Association of Clinical Biochemistry); and Arthur Rubinstein (medicine, University of Chicago). Cortivo testified that the hypodermic needle tainted with insulin on the outside (but not inside) would have been dipped in insulin but not injected; injecting it through flesh would have wiped it clean. Evidence also showed that Sunny's hospital admission three weeks before her final coma showed she had ingested at least 73 aspirin tablets, a quantity that could only have been self-administered, and which indicated her state of mind. Dershowitz, in his book Taking the Stand, writes about von Bülow's dinner party after he was found not guilty at his trial.
=== Surgical devices === Even with all the precautions taken by medical professionals, infection reportedly occurs in up to 13.9% of patients after stabilization of an open fracture, and in about 0.5-2% of patients who receive joint prostheses. To reduce these numbers, the surfaces of the devices used in these procedures have been altered in hopes of preventing the growth of the bacteria that leads to these infections. This has been achieved by coating titanium devices with an antiseptic combination of chlorhexidine and chloroxylenol. This antiseptic combination successfully prevents the growth of the five main organisms that cause medical-related infections, which include Staphylococcus epidermidis, Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Candida albicans. Peptide-based gel coating with intrinsic antibacterial activity against Methicillin-resistant Staphylococcus aureus, was also shown to inhibit colonization of titanium implants in mice.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.